Biotech Values

[beach_trades]

TEAR-Roth Capital Medical Technology Analyst Matt Dolan

February 23, 2012
TearLab Osmolarity System

We recently initiated coverage on TearLab (TEAR) as one of our micro-cap medical device ideas. The company has developed an osmolarity diagnostic for Dry Eye Disease in the physician office setting. In December and January, TearLab received a positive code decision from Medicare and its CLIA waiver from the FDA, which we think is a transformative event. We have covered a lot of diagnostic companies that sell into the physician office setting and therefore understand the impact these developments could have on a company's commercial success. We expect these two milestones will really open the gate for the company to start placing a lot of its systems out in the field and allow revenue to scale up in a significant way in the next few years.

http://seekingalpha.com/article/388961-a-talk-with-roth-capital-medical-technology-analyst-matt-dolan?source=yahoo